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ABSTRACT
Mammalian target of rapamycin (mTOR) is a central regulator of growth and 
metabolism. mTOR resides in two distinct multi-protein complexes – mTORC1 
and mTORC2 – with distinct upstream regulators and downstream targets. While 
it is possible to specifically inhibit mTORC1 with rapamycin, or inhibit both mTOR 
complexes together with ATP pocket directed mTOR kinase inhibitors, it is not possible 
to assess the specific roles for mTORC2 pharmacologically. To overcome this, we 
have developed a novel, inducible, dominant negative system for disrupting substrate 
recruitment to mTORC2. Previously we identified the mTORC2 specific subunit Sin1 as 
a direct binding partner for AGC kinases Akt and PKC. Sin1 mutants, which retain the 
ability to bind Rictor and mTOR, but fail to recruit their AGC client kinases, inhibit AKT 
and PKC priming and block cell growth. In this study, we demonstrate that uncoupling 
mTORC2 from AGC kinases in DLD1 colon cancer cells inhibits Akt activation and 
blocks tumour growth in vivo. Further we demonstrate, using time resolved two-site 
amplified FRET (A-FRET) analysis of xenograft tumours, that inhibition of tumour 
growth correlates with the degree of mTORC2 uncoupling from its downstream 
targets, as demonstrated for Akt. These data add weight to the body of evidence that 
mTORC2 represents a pharmacological target in cancer independently of mTORC1.
INTRODUCTION
The mammalian target of rapamycin (mTOR) is a 
key regulator of eukaryotic cell growth and represents a 
major drug target in numerous cancers [1-3]. There are 
two evolutionary conserved branches to mTOR signalling 
mediated by two multi-protein complexes, mTORC1 and 
mTORC2, with distinct roles in cell growth control [4]. 
While these complexes share many subunits, they are 
defined by unique protein components, including raptor 
for mTORC1 or Sin1 and Rictor for mTORC2. These 
unique subunits confer distinct regulation, localisation 
and substrate specificities for the two complexes. 
Structural and biochemical studies are now delineating 
the precise mechanisms governing upstream regulation 
and downstream target recruitment of the two complexes
Among the key targets for the mTOR complexes 
are AGC family kinases, including Akt, p70S6 kinase, 
SGK and PKC. AGC kinase activity is typically regulated 
by PDK1 mediated phosphorylation of the generic 
kinase domain activation loop and mTOR mediated 
phosphorylation of conserved hydrophobic- and turn-
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motifs within a C-terminal kinase domain extension. These 
phosphorylations cooperate to fully activate the AGC 
kinase domain [5]. mTORC1 and mTORC2 target distinct 
AGC family members. Thus, mTORC1 phosphorylates 
p70S6K to regulate protein synthesis, while mTORC2 
targets Akt, PKC and SGK downstream of various growth 
factor stimuli to regulate diverse cellular functions [6-11].
The emergence and early promise of mTOR 
inhibitors has provided evidence that targeting of 
mTORC1 with rapalogues, or both mTORC1 and 
mTORC2 with active site directed inhibitors, may be 
beneficial therapeutically in a number of malignancies. 
Dose limiting toxicities [12] and potential caveats in the 
targeting of mTORC1 under nutrient deprived conditions 
[13, 14] have also made the development of specific 
mTORC2 directed therapies an attractive proposition. A 
number of lines of evidence suggest mTORC2 targeting 
alone might be beneficial. Prostate specific deletion of 
Rictor was found to supress PTEN driven tumourigenesis 
downstream of Akt in mice and mTORC2 mediates Akt 
dependent chemotherapy resistance in PTEN null glioma 
patients [15], indicating the importance of mTORC2 as a 
PI3kinase effector pathway. mTORC2 can also regulate 
cancer metabolism, survival under hypoxic/nutrient 
deprived conditions, drug resistance and metastasis 
variously downstream of Akt, SGK and PKC [3, 16, 
17]. Finally, a number of functional cancer promoting 
mutations or amplifications have been identified in the 
mTORC2 components Sin1 and Rictor reinforcing distinct 
mTORC1 independent roles in cancer [18].
mTORC2 specific inhibitors remain to be described 
and in their absence alternative means are required to 
specifically assess this pathway as an independent target 
[19]. We previously identified Sin1 as a direct binding 
partner of the AGC kinases Akt and PKC and mapped 
binding to the CRIM (Conserved Region In Middle) 
domain. We went on to demonstrate that incorporation of 
AGC binding deficient mutants of Sin1 into endogenous 
mTORC2 uncoupled mTORC2 from these target effectors 
and influenced cellular growth in 3D. Here we have 
exploited this novel inducible dominant negative Sin1 
strategy to uncouple mTORC2 signalling in a DLD1 colon 
cancer model. This reveals that suppression of mTORC2 
alone is capable of restricting tumour development and 
further supports the rationale for developing mTORC2 
specific drugs. 
RESULTS
Sin1 truncation mutants incorporate into 
endogenous mTORC2 in DLD1 cells and suppress 
Akt phosphorylation
We previously identified that Sin1 interacts 
directly with AGC client kinases in yeast-2-hybrid and 
HEK293 pull-down assays, and mapped the interaction 
to the CRIM domain of Sin1 [21]. In this previous study, 
inducible expression of Sin1 mutants, which retain the 
C-terminal mTORC2 binding domain, but lack an intact 
CRIM domain, incorporate into the endogenous mTORC2 
complex and inhibit hydrophobic motif targeting of both 
PKC and Akt in HEK293 cells. In order to examine a role 
in tumour growth we developed DLD1 colon cancer cell 
lines expressing doxycycline inducible myc-tagged full-
length or truncated Sin1, which retains the mTORC2 
binding domain (∆Sin1 - residues 1-192; Figure 1A). 
∆Sin1 was selected from our panel of Sin1 constructs as 
it was the most efficient at uncoupling mTORC2 from 
both Akt and PKC phosphorylation in HEK293 cells [21]. 
This likely reflects the deletion of both the AGC recruiting 
CRIM domain and the membrane targeting PH domain 
[21, 22]. Myc-Sin1 constructs were introduced into FRT-
DLD1 cells (courtesy of Stephen Taylor) using the FRT-
TRexTM system (Invitrogen). Induction with doxycycline 
induced low-level expression of the constructs at the 
expected sizes (Figure 1B). Immune precipitation of 
the myc-tagged Sin1 co-purified both Rictor and mTOR 
confirming incorporation into the endogenous mTORC2 
complex (Figure 1C). Myc-FL-Sin1 can also be detected 
using either Sin1 or myc (9E10) antibodies. Detection of 
the truncated ∆Sin1 in myc immunoprecipitates was not 
possible as the Sin1 epitope is absent and background 
from precipitating IgG obscured detection with the 
myc antibody. However, complex components were not 
purified in un-induced cells, confirming expression of 
the construct and specificity of the pull downs. Levels of 
mTOR and Rictor expression were unaltered by inducible 
Sin1 expression (Figure 1C and 1E); as previously 
described, detection of Sin1 in cell lysates is hampered 
by non-specific antibody cross reactivity [21]. We were 
unable to detect the localisation of the induced myc-tagged 
constructs by immunofluorescence, perhaps due to epitope 
masking or low levels of expression.
In order to examine and quantify the integrity 
of the mTORC2 complex, and the degree to 
which endogenous Sin1 has been displaced, we 
immunoprecipitated mTORC2 using either Rictor or 
Sin1 polyclonal antibodies (Figure 1D). Induction of 
∆Sin1 expression resulted in reduced Rictor and mTOR 
in Sin1 immunoprecipitates. Endogenous Sin1 is also 
lost from Rictor immunoprecipitates, but levels of mTOR 
remain unchanged. Quantitation of mTORC2 complex 
components immunoprecipitated with Rictor before and 
after doxycycline induction across multiple experiments 
allows assessment of the penetrance of complex disruption 
(Figure 1F). ∆Sin1 expression resulted in a seven-
fold reduction in levels of associated endogenous Sin1 
(0.14 ± 0.04; average ± STD; n = 3) with no change in 
levels of associated mTOR. Together these data indicate 
that the ∆Sin1 construct incorporates into >80% of the 
endogenous mTORC2 complex without affecting the net 
expression levels of the complex. Levels of endogenous 
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Figure 1: Truncated Sin1 displaces endogenous Sin1 from mTORC2 in DLD1 colon cancer cells. A. Schematic indicating 
the domain structure of Sin1 and the constructs used to displace endogenous Sin1 from mTORC2. B. Expression of myc tagged Sin1 
constructs can be detected only after induction with Doxycycline (Dox). Cells were treated with 100nM of doxycycline (+) for 72 hours 
and expressed proteins were detected by immunoblot of whole cell lysates with anti-myc (9E10) antibodies. C. and D. Sin1 constructs 
incorporate into mTORC2 and displace endogenous Sin1. Constructs were induced for 72 hours prior to immune precipitation. (C) mTORC2 
subunits, mTOR and Rictor, only appear in myc immunoprecipitates after induction with doxycycline (Left panels); myc-∆Sin1 cannot 
be directly detected in precipitates due to secondary antibody cross reaction with precipitating IgG. Right panels indicate unchanging 
expression levels of Rictor and mTOR in immune precipitation input lysates, which is further quantified from 3 independent experiments 
E. Endogenous Sin1 and Rictor immunoprecipitates demonstrate displacement of endogenous Sin1 from mTORC2. Following induction, 
band shifted myc-tagged FL Sin1 can be detected in Sin1 and Rictor precipitates (Left panels). Truncated ∆Sin1 can be detected in Rictor, 
but not Sin1, immunoprecipitates as the Sin1 antibody epitope is deleted from ∆Sin1. F. Quantification of Sin1 levels detected in Rictor 
immunoprecipitates indicates the level of endogenous mTORC2 disruption following Sin1 construct induction (data are mean +/- S.D; n = 
3). Myc-∆Sin1 displaces >80% of endogenous Sin1 while levels of myc-FL Sin1 associated with Rictor are comparable with endogenous 
Sin1 levels.
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Figure 2: ∆Sin1 expression suppresses Akt activation but not p70S6K activation in DLD1 cells. A. Following 72 hours 
doxycycline (Dox) induction of Sin1 constructs, or 30 minute incubation with 1µM PP242 or 100nM rapamycin (Rapa), cell lysates 
were probed with the indicated antibodies. B. Quantification from 3 independent experiments indicates that Sin1∆1-192 but not Sin1-FL 
significantly inhibits phosphorylation of the mTORC2 target Akt on S473 but not the mTORC1 targeted p70S6K on T389. Conversely 
rapamycin selectively inhibits T389 phosphorylation while PP242 inhibits both. C. and D. Cells were serum starved (0.5% Serum) overnight 
(O/N)prior to stimulation with 10% Serum for the times indicated. Phosphorylation of Akt on pT308 and pS473 were assessed relative to 
total Akt. GAPDH indicates protein loading. Quantification represents mean +/- S.D (n = 3). Statistical significance was assessed by 1-way 
(B) or 2-way (D) ANOVA and Bonferroni post hoc tests; *p < 0.05; **p < 0.01; ***p < 0.001.
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Sin1 immunoprecipitated by the Sin1 polyclonal were 
also reduced to the same degree (Relative Intensity 0.16 
± 0.14) indicating that displaced endogenous Sin1 is 
unstable and degraded [21]. Induction of myc-FL Sin1 had 
little effect on the total levels of Sin1 co-precipitated with 
Rictor (1.06 ± 0.2) although the endogenous doublet is 
entirely replaced by the band shifted myc-FL Sin1 (Figure 
1D); as for ∆Sin1, endogenous Sin1 is displaced from Sin1 
immunoprecipitates following myc-FL Sin1 incorporation 
into mTORC2. Assessment of mTOR and Rictor by 
immunofluorescence did not reveal any observable change 
in sub-cellular localisation in response to incorporation of 
either myc-Sin1 protein (Supplementary Figure S1).
Consistent with our previous findings in HEK293 
cells, ∆Sin1 expression in DLD1 cells suppressed 
Akt Ser473 phosphorylation but had no effect on 
phosphorylation of the mTORC1 target p70S6K 
Thr389 (Figure 2A and 2B). In contrast, inducible 
expression of full-length myc-Sin1 affected neither Akt 
nor p70S6K (Figure 2B). Rapamycin and the mTOR 
catalytic inhibitor, PP242, were used to confirm the 
respective targeting of p70S6K and Akt by mTORC1 and 
mTORC2 pharmacologically. To assess acute stimulation 
of Akt phosphorylation, serum starved DLD1 cells 
were stimulated with 10% serum. Serum induced Akt 
phosphorylation on both Ser473 and the PDK1 targeted 
activation loop (Thr308) w significantly inhibited by 
∆Sin1 expression (Figure 2C and 2D). This likely reflects 
the combination of direct suppression of mTORC2 
dependent S473 phosphorylation and reduced stability of 
activation loop phosphorylation in the absence of Ser473 
phosphorylation.
Together these data demonstrate that inducible 
expression of Sin1 constructs can be used to modulate 
mTORC2 complex functionality while maintaining 
complex integrity. In contrast, Sin1 or Rictor ablation 
results in complex disruption with unknown adaptive 
consequences [10, 23].
Suppression of mTORC2 activity blocks DLD1 
xenograft tumour growth
In order to assess a role for mTORC2 in tumour 
growth we conducted subcutaneous xenograft studies in 
NOD/SCID mice. Mice were injected with DLD1 ∆Sin1 
tumour cells on both flanks and mice were randomly 
assigned to two groups: control and doxycycline. For 
doxycycline treatment, to induce ∆Sin1 expression, 
drinking water was supplemented with 1% sucrose 
(w/v) and 2mg/ml doxycycline; control mice were 
maintained on 1% sucrose alone as a vehicle control. 
Tumour growth was monitored three times weekly by 
caliper measurements and the experiment was terminated 
before tumour burden reached the maximum permitted 
volume. Doxycycline treatment significantly inhibited 
tumour incidence and average tumour burden (Figure 3A 
and 3B). Interestingly however, when we compared the 
growth rate of established individual tumours within the 
doxycycline group, doubling times were similar to those 
in the untreated group. Thus, despite a decrease in average 
tumour burden and incidence, tumours were able to grow 
at control rates once established. 
To mimic therapeutic targeting we also assessed the 
effect of ∆Sin1 induction on the growth of established 
tumours (Figure 3E and 3F). Mice were injected with 
DLD1 ∆Sin1 tumour cells and assigned randomly to 
control or doxycycline groups when tumours reached 
50mm3. Average tumour growth was modestly reduced by 
∆Sin1 induction and individual tumour growth rate was 
also suppressed. In contrast to xenograft growth, ∆Sin1 
expression did not affect growth of DLD1 cells under 
standard 2D cell culture conditions as previously described 
for HEK293 cells (data not shown). This concurs with the 
observation that Sin1 (unlike Rictor) knockout fibroblasts 
do not show a growth deficit in cell culture [10, 24]. We 
conclude that inducible suppression of mTORC2 function 
in vivo can suppress mTORC2 target phosphorylation and 
impede tumour development. 
Inhibition of tumour growth correlates with the 
degree of Akt suppression in vivo
To determine the whether ∆Sin1 was able to 
target mTORC2 function in vivo we conducted a time 
resolved amplified FRET (A-FRET) analysis of Akt 
activation status in tumour sections [20]. Here, we used 
an antibody directed against total Akt (mouse mAb) 
paired with either phospho-Akt Ser473 or phospho-Akt 
Thr308 (rabbit mAb). Total Akt was detected by Anti-
mouse Fab-ATTO488 and pAkt (Ser473, Thr308) were 
detected by an Anti-rabbit Fab-HRP secondary which was 
further detected by using Alexa-594-TSA assay. FRET 
efficiency was assessed by monitoring the reduction 
in the fluorescence lifetime of the donor fluorophore 
(ATTO488) across tumour sections; donor lifetime maps 
in the presence of the acceptor provide a direct measure of 
Akt phosphorylation (Figure 4A and 4B). FRET efficiency 
was quantified across a cohort of control and doxycycline 
tumours collected at a single time point. For each tumour, 
multi-region comparisons allow assessment of variation in 
the levels of Akt phosphorylation both within and between 
tumours. Both Ser473 and Thr308 phosphorylation 
were on average significantly lower in tumours from 
doxycycline treated mice compared with untreated mice 
(Figure 4C, 4D and Supplementary Figure 2). However, a 
number of tumours in the doxycycline group demonstrated 
FRET efficiencies comparable with tumours from the 
control groups and significantly, levels of Akt activation 
were found to correlate with tumour size (Figure 5). This 
implies that disruption of mTORC2 function can impede 
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Figure 3: ∆Sin1 expression suppresses DLD1 subcutaneous tumour growth in NOD/SCID mice. Mice were inoculated 
with 106 DLD1 cells on both flanks and assigned randomly to control or doxycycline (Dox) groups. Tumour burden A. and incidence B. 
per inoculation were assessed 3 times weekly. Data are mean +/- S.E.M. Statistical significance was assessed by ANOVA and Bonferroni 
post hoc test; **p < 0.01; ***p < 0.001. C. Examples of individual tumour growth rates; curves indicate exponential growth curve best fit 
to estimate growth rates. D. Growth rate of tumours does not differ significantly between control and doxycycline cohorts. Data are mean 
+/- STD E. Mice were inoculated on a single flank with DLD1 cells. Once tumours had reached a volume of 50mm3 mice were randomised 
into vehicle and Dox treated groups. Times indicated are post-1st treatment and statistical analysis was conducted as for A. This data is 
derived from a single cohort of animals. F. Growth rates for individual tumours from (E) are illustrated (student's t-test; *p < 0.05.
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Figure 4: Time resolved amplified FRET indicates significant suppression of Akt activation following ∆Sin1 induction. 
Example fluorescence intensity images and donor lifetime maps of tumours from four independent control (A) and doxycycline (B) treated 
mice. Tumours were stained for either panAkt (Donor; D) alone (Left panels) or panAkt and pS473 (Acceptor; A) together (Right panels). 
In the doxycycline cohort, representative examples of tumours showing high and low FRET efficiency are shown. C. and D. Multiple 
regions (n = 3-9) were quantified for each tumour and average FRET efficiency compared for control and doxycycline (Dox) cohorts; both 
pT308 and pS473 were significantly suppressed in the doxycycline cohort (student’s t-test; *p < 0.05; **p < 0.01) and results are the mean 
+/- S.D. FRET efficiency for individual tumour regions are presented in Supplementary Figure 2.
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tumour growth but that compensatory re-activation of 
downstream targets may provide an escape mechanism 
allowing tumours to re-establish growth rates comparable 
with control tumours.
DISCUSSION
The first generation of mTOR targeting drugs stem 
from the eponymous allosteric inhibitor of mTORC1, 
rapamycin. Rapamycin and its analogues (rapalogues) 
have been approved for the treatment of a number of 
malignancies, including Renal Cell Carcinoma, HER2 
negative breast cancer and various neuroendocrine 
tumours [2, 3]. Despite some success, rapalogues exhibit a 
number of undesirable biochemical properties. Firstly, they 
only partially inhibit mTORC1 signalling in a substrate 
specific manner, as the key target 4E-BP1 escapes 
complete inhibition. Furthermore, mTORC2 signalling 
to pro-growth pathways, including Akt, remains intact 
and is in fact amplified as inhibition of mTORC1 releases 
negative feedback control of the PI3kinase/mTORC2/Akt 
pathway. Finally, as rapalogues are generally cytostatic, 
prolonged treatment regimes may be required with 
unfavourable toxicity profiles at effective doses. 
Second generation active site directed mTOR 
inhibitors, that target both mTORC1 and mTORC2, 
demonstrate significantly improved anti-cancer activity in 
preclinical models when compared with rapalogues [25-
30]; a variety of these mTOR inhibitors are now being 
explored in the clinic with mixed results [12, 31-34]. 
While targeting both arms of mTOR signalling shows 
promise, strategies for selective targeting of mTORC2 
alone could be beneficial or indeed a preferred strategy in 
some diseases. In particular, PTEN/PI3K mutant tumours, 
and tumours where activating mutations or amplifications 
in mTORC2 components have been identified may 
respond to more selective interventions with reduced 
Figure 5: Tumour growth inhibition correlates with Akt suppression. Each point indicates a single tumour and error bars 
indicate the mean +/- S.E.M. of quantified tumour regions. For both Akt pS473 (top graphs) and pT308 (bottom graphs) phosphorylation 
significantly correlates with tumour volume in the doxycycline (Dox) tumours (right graphs) but not the control tumours (vehicle treated; 
Veh) (left graphs). The Pearson correlation coefficient (r) and statistical significance for each condition is indicated.
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liabilities. Additionally, there are situations where 
targeting mTORC1 may be ill advised. For example, under 
nutrient deprived conditions, inhibition of mTORC1 has 
been shown to promote tumour growth by enhancing 
pro-survival autophagy and cellular use of proteins as 
an energy source [13, 14]. Undesired consequences 
associated with mTORC1 inhibition, such as immune 
suppression, might also be avoided and this has particular 
relevance to combination studies in this era of immune-
oncology.
In order to model the effects of targeting mTORC2 
alone, strategies which perturb the function of the 
mTORC2 specific subunits Sin1 or Rictor are necessary. 
Rictor and Sin1 null cells from knockout mice have 
thus been instrumental in defining mTORC2 complex 
regulation and targets. Deletion of either Sin1 or Rictor 
results in complete loss of the mTORC2 complex [10, 
35]. As an alternative strategy, we developed an inducible 
system for disrupting recruitment of mTORC2 client 
kinases to the endogenous complex. Here, truncated 
Sin1, which cannot bind to AGC kinases, replaces 
endogenous Sin1 without altering the net levels of 
assembled cellular mTORC2 complex. In a previous 
study we found that truncations, which delete both the 
CRIM domain (responsible for AGC kinase recruitment 
[36]) and the C-terminal PH domain, were the most 
effective at supressing Akt phosphorylation. The Sin1 
PH domain has recently been shown to mediate direct 
inhibition of the mTOR kinase domain, analogous to 
the inhibition of Akt by its own C-terminal PH domain 
[22]. Binding of the Sin1 PH domain to PtdIns(3,4,5)P3 
downstream of PI3 kinase both releases inhibition and co-
localises mTORC2 with its substrate Akt. Interestingly, 
in a previous study, we found that incorporation of PH 
domain disrupted Sin1 into mTORC2 did not significantly 
modify basal Akt phosphorylation in HEK293 cells [21]. 
This somewhat counterintuitive observation likely reflects 
the ability of Sin1 to directly interact with Akt combined 
with the dis-inhibition of mTOR by PH domain deleted 
Sin1. These observations are consistent with the model 
wherein membrane associated, PDK1 phosphorylated 
Akt is recruited to mTORC2 via Sin1, promoting 
phosphorylation of Sin1, activation of mTORC2, 
triggering S473 phosphorylation on Akt [21, 37].
Despite regulation through a genetic mechanism, we 
have generated a system where we can inducibly ablate 
approximately 90% of cellular TORC2 activity following 
doxycycline administration; this pharmacomimetic 
system provides unique insight into the potential in 
vivo response to mTORC2 blockade. Encouragingly, 
suppression of mTORC2 significantly impeded tumour 
development in our xenograft model. Two-site amplified 
FRET analysis revealed target suppression in vivo with 
significant reduction in phosphorylation of Akt on both 
mTORC2 targeted Ser473 and PDK1 targeted Thr308 (a 
weaker inhibitory effect was observed on this latter site). 
Associated with the direct effect of mTORC2 inhibition, 
loss of Thr308 was also observed in cell culture. 
This likely results from reduced stability of Thr308 
phosphorylation in the absence of Ser473 mediated kinase 
domain stabilisation. An alternative mechanism, where 
disruption of PIF pocket dependent recruitment of PDK1 
in the absence of Akt Ser473 phosphorylation is unlikely 
to explain Thr308 reduction, as blocking this interaction 
is not sufficient to block Akt activation by PDK1 [38]. 
Interestingly, once tumours became established growth 
rates were comparable in both control and mTORC2 
supressed groups and the degree of pAkt suppression 
correlated with  inhibition of tumour growth. The high 
level of Akt phosphorylation in more rapidly growing 
tumours may be explained through multiple mechanisms. 
Firstly, Akt Ser473 may be reacquired through adaptive 
changes, in the absence of mTORC2; retention of Akt 
Ser473 has been observed in tissue-specific Rictor 
knockouts [39], potentially involving DNA-PK, which 
can also mediate this phosphorylation [40]. Alternatively, 
up regulation of the less efficient mTORC2 complex or 
expansion of ∆Sin1 null subpopulations of DLD1 cells 
may account for the escape. Clearly the mechanism 
underlying mTORC2 blockade escape warrants further 
investigation in addition to exploring combination 
regimes, however the significance of the current findings 
is evident - selective inhibition of mTORC2 elicits a 
tumour suppressive response.
MATERIALS AND METHODS
Cell culture and tumour inoculation
FRT-DLD1 cells were cultured in DMEM, 
10% foetal bovine serum, penicillin (50 units/ml) and 
streptomycin (0.05 mg/ml) in 10% CO2. Tetracycline-
inducible Sin1 lines were generated using the pcDNA5.0 
FRT T-RexTM system (Invitrogen) according to the 
manufacturer’s instructions. Sin1 expression was induced 
with 100 ng/ml tetracycline. Animal studies were 
compliant with UK Home Office regulations and carried 
out under license PPL 70/8066. Female NOD/SCID 
mice were inoculated subcutaneously on the hind flank 
with 1x106 DLD1 cells before being assigned randomly 
to control and doxycycline cohorts. Drinking water 
was supplemented with 1 % sucrose (w/v) and 2mg/ml 
doxycycline. Tumour growth was monitored by caliper 
measurements twice weekly and volume calculated as (w2 
x l)/2. Excised tumours were fixed in formalin and paraffin 
embedded for pathology and FRET analysis.
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Antibodies and reagents
Mouse anti-Akt/PKB (A-FRET) mAb (SKB1) was 
from Millipore (#: 05-591), anti-pAkt (Thr308) (D25E6) 
rabbit (#: 13038S), anti-pAkt (Ser473) (D9E) rabbit (#: 
4060S), and anti-Akt (immunoblot) mAb (#:40D4) were 
obtained from Cell Signaling Technology. Affinity-purified 
F(ab’)2 fragments Perox-Apure, Fab-Frag Anti-Rabbit 
-HRP (#: 711-036-152) were purchased from Jackson 
ImmunoResearch, Suffolk, UK. Peroxidase Suppressor 
(#35000) and Tyramide Signal Amplification (TSA) kit 
with Alexa Fluor 594 tyramide (#: T-20925) was purchased 
from Thermo Fisher Scientific, UK. ATTO488 NHS-ester 
dye (#: 41698-1MG-F) from Sigma. Sin1 (NB110-40424), 
Rictor (NB100-612) and mTOR (NBP-19855) polyclonal 
antibodies were purchased from Novus Biologicals. 
Anti-myc (9E10) was prepared by the In-House antibody 
facility. Sin1 mAb was from R&D Systems (MAB8168).
Immunoprecipitation and immunoblotting
For immunoprecipitation of mTORC2, cells were 
lysed in 0.3% CHAPS, 40 mM Tris pH 7.4, 120 mM 
NaCl, 1 mM EDTA, 50 mM NaF, 10 mM Pyrophosphate, 
10 mM β-glycerophosphate, 2 mM Na orthovanadate 
supplemented with cOmpleteTM protease inhibitor cocktail 
(Roche). 2 µg of antibody was conjugated to protein G 
DynaBeads (Invitrogen) and incubated overnight with 
1-2mg centrifuged lysate and washed four times with 
lysis buffer. Immunoprecipitates or cell lysates were 
resolved by SDS-PAGE, transferred to nitrocellulose and 
incubated with designated antibodies overnight. Bands 
were visualised and quantified using an AI600 imaging 
system (GE Healthcare), using HRP conjugated secondary 
antibodies and enhanced chemiluminescence.
Conjugation of Fab-fragment with ATTO488-
NHS dye
ATTO488-NHS conjugation to the anti-mouse-
specific Fab secondary antibody (1mg/ml) was performed. 
Briefly, the ATTO488-NHS-ester dye was reconstituted 
in anhydrous DMF to a concentration of 1mg/ml and 
added (125µg of dye/1mg of protein) to the Fab fragment 
antibody solution. The reaction mixture was incubated 
with constant agitation at room temperature for 1 hour. 
Purification of labelled antibodies was performed using 
pre-equilibrated (PBS, pH 7.2) gravity flow PD-10 dye 
removal columns. The dye: protein ratio required for these 
experiments should not exceed a 4:1 ratio. 
Quantification of pAkt (pT308/p473) in mouse 
FFPE tumour by time resolved two-site amplified 
FRET (A-FRET) assay
For the acquisition of donor (ATTO488) fluorescent 
lifetime an automated multiple frequency lifetime 
imaging microscope (Lambert Instruments) was used. 
Two identical tumour sections (4 μm) were de-waxed, 
rehydrated and subjected to heat antigen retrieval by 
microwaving in Tris-EDTA (pH 9.0) buffer, for 10 
minutes. Sections were then incubated in freshly prepared 
sodium borohydride (1mg/ml in PBS) buffer for 10min 
at RT, followed by blocking with 1% BSA/PBS. Tissue 
sections were incubated with peroxidase suppressor for 
15min. For the A-FRET assay, the first slide was incubated 
with mouse anti-panAkt (1:50), and the second slide with 
mouse anti-panAkt (1:50) plus rabbit anti-pT308 (1:200) 
primary antibodies, overnight at 4°C. The first slide 
was further immunolabeled with (donor fluorophore) 
ATTO488-conjugated anti-mouse Fab fragment secondary 
antibody (20µg/ml). The second slide was immunolabeled 
with ATTO488-conjugated anti-mouse Fab fragment 
(20µg/ml) and HRP-conjugated anti-rabbit Fab fragment 
secondary antibody (10µg/ml), which was detected by 
using (acceptor fluorophore) Alexa-594-TSA assay. These 
slides were mounted with ProLong® Gold anti-fade. The 
donor lifetimes of ATTO488 were determined from at 
least 3 regions from each section with elevated donor 
intensity. Lifetime data was analysed using a purpose-built 
algorithm and the FRET efficiency was calculated using 
the following equation: Ef = 1-(tDA/tD)*100%; where tD 
is donor lifetime and tDA is donor plus acceptor lifetime 
[20]. After the FRET quantification, the above slides were 
scanned under a confocal microscope to assess the co-
localization of panAkt and pT308/p473. 
Abbreviations
mTOR, Mammalian target of rapamycin; mTORC2 
Mammalian target of rapamycin complex 2. PKC, protein 
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